In vitro drug toxicity assays revealed the BCR-ABL-like leukemic cells were 73 times more resistant to l-asparaginase and 1.6 times more resistant to daunorubicin when compared to other precursor B-ALL cases. Here, BCR is linked to acute lymphoblastic leukemia.